Kennedy Capital Management LLC Cuts Stake in Charles River Laboratories International, Inc. $CRL

Kennedy Capital Management LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,345 shares of the medical research company’s stock after selling 30,019 shares during the quarter. Kennedy Capital Management LLC’s holdings in Charles River Laboratories International were worth $8,094,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Charles River Laboratories International by 5.1% during the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock valued at $644,980,000 after purchasing an additional 208,586 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after purchasing an additional 516,521 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its holdings in Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock valued at $293,555,000 after buying an additional 144,732 shares during the period. Invesco Ltd. raised its stake in Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock worth $187,712,000 after buying an additional 128,785 shares in the last quarter. Finally, Ariel Investments LLC lifted its holdings in Charles River Laboratories International by 3.1% during the first quarter. Ariel Investments LLC now owns 1,100,776 shares of the medical research company’s stock worth $165,689,000 after buying an additional 33,449 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $184.08 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $202.72. The company has a market cap of $9.06 billion, a PE ratio of -118.00, a P/E/G ratio of 6.53 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The business has a 50-day simple moving average of $174.12 and a two-hundred day simple moving average of $161.14.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.59 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CRL shares. William Blair upgraded Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. TD Cowen reduced their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a report on Monday, November 10th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price target for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. Finally, Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $190.86.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).